Jeff Keats
Ariadne Diagnostics (United States)(US)
Publications by Year
Research Areas
Chronic Myeloid Leukemia Treatments, Lung Cancer Treatments and Mutations, Chronic Lymphocytic Leukemia Research, Click Chemistry and Applications, Cancer therapeutics and mechanisms
Most-Cited Works
- → Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant(2010)358 cited
- → The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models(2016)321 cited
- → Structural Mechanism of the Pan‐BCR‐ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance(2010)282 cited
- → Crystal Structure of the T315I Mutant of Abl Kinase(2007)103 cited
- → Structural Basis of Src Tyrosine Kinase Inhibition with a New Class of Potent and Selective Trisubstituted Purine‐based Compounds(2005)86 cited
- → 9-(Arenethenyl)purines as Dual Src/Abl Kinase Inhibitors Targeting the Inactive Conformation: Design, Synthesis, and Biological Evaluation(2009)46 cited
- → Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR–ABL including the T315I gatekeeper mutant(2011)18 cited
- → SAR of Carbon‐Linked, 2‐Substituted Purines: Synthesis and Characterization of AP23451 as a novel Bone‐Targeted Inhibitor of Src Tyrosine Kinase With In Vivo Anti‐Resorptive Activity(2008)15 cited
- → Orally Active Inhibitors of the Imatinib Resistant Bcr-Abl Mutant T315I.(2006)10 cited
- → Abstract C12: Identification of biomarkers and pathways associated with response to the DOT1L inhibitor Pinometostat (EPZ-5676) in MLL-r leukemia(2015)1 cited